DHCR7-DT and Acute hepatitis: In February 2023 (week 42 since recurrence), after seven cycles of durvalumab, the patient developed grade 3 acute hepatitis [3], with the following values: Alanine transaminase (ALT) 530 U/L (10.6x ULN), Aspartate transaminase (AST) 318 U/L (6.4x ULN), total bilirubin 1.14 mg/dL (normal), Alkaline phosphatase (AP) 385 U/L (3.0x ULN), and Gamma-glutamyltransferase (GGT) 382 U/L (6.4x ULN), as shown in Fig. 1.